Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-05-31-Speech-3-173"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20060531.16.3-173"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"I am pleased with this proposal, because I am convinced that it will result in more medicinal products developed and tested specifically for children being launched onto the market. This is, above all, of great importance for young patients suffering from serious illnesses such as cancer or disorders of the immune system.
We should, however, not lose sight of the ethical side of the matter, and must prevent children from being used as guinea pigs. That is why it is good that double testing is being cut out by the possibility of research already being done in third countries being valid.
Since estimates show that 50 to 90% of the medicinal products that are currently being used in paediatrics are never specifically studied or approved for use in that age category, the negative and positive effects of their application are virtually unknown. It is therefore a good thing that European legislation should promote research into medicinal products that have been developed specifically for children and that we can thus put an end to this uncertainty."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples